Press Releases

• INTELISWAB® COVID-19 RAPID TESTS RECEIVE U.S. FDA AUTHORIZATION FOR PEDIATRIC USE AND COMPANY LAUNCHES NEW INTELISWAB® CONNECT REPORTING APP
• U.S. FDA AUTHORIZES INTELISWAB® COVID-19 RAPID TESTS FOR OTC SINGLE-USE, AT-HOME TESTING FOR SYMPTOMATIC PEOPLE AND ACCEPTS DATA FOR DELTA VARIANT DETECTION
• ORASURE TO RECEIVE UP TO $13.6 MILLION FROM BIOMEDICAL ADVANCED RESEARCH DEVELOPMENT AUTHORITY TO SUPPORT INTELISWAB® COVID-19 RAPID TEST 510(K) CLEARANCE AND CLIA WAIVER
• ORASURE RECEIVES $205 MILLION PROCUREMENT CONTRACT FOR INTELISWAB® FROM THE DEFENSE LOGISTICS AGENCY TO SUPPLY OVER-THE-COUNTER (OTC) KITS AS PART OF NATIONAL PANDEMIC RESPONSE
• ORASURE TECHNOLOGIES RECEIVES THREE EMERGENCY USE AUTHORIZATIONS FOR ITS COVID-19 RAPID ANTIGEN TESTS FOR NON-PRESCRIPTION (OTC), PROFESSIONAL AND PRESCRIPTION USE
• ORASURE TECHNOLOGIES SUBMITS COVID-19 RAPID ANTIGEN PRESCRIPTION HOME SELF-TEST AND PROFESSIONAL TEST TO FDA FOR EMERGENCY USE AUTHORIZATION